1:12 PM
 | 
Mar 02, 2018
 |  BioCentury  |  Finance

Genome toolbox

How Inscripta complements genome reading, writing plays in investors’ portfolios

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing.

New investor Mérieux Développement and existing investor Paladin Capital led the round, which closed on Feb. 28, joined by existing investors Venrock, Foresite, MLS Capital and NanoDimension.

Inscripta is the only gene editing company in Mérieux’s and Paladin’s portfolios.

“We’ve tried to make investments that cut across each of the different parts of the chain.”

Read the full 395 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >